Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.88 EUR | 0.00% | 0.00% | 0.00% |
20/05 | Global markets live: Apple, Tesla, Pfizer, AstraZeneca, Microsoft... | |
17/05 | US Equity Markets Close Mixed Friday | MT |
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Its low valuation, with P/E ratio at 6.79 and 7.49 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- This company will be of major interest to investors in search of a high dividend stock.
- Sales forecast by analysts have been recently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Banks
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
0.00% | 11.09B | - | ||
+14.98% | 562B | C+ | ||
+15.30% | 304B | C+ | ||
+24.87% | 256B | C+ | ||
+23.32% | 212B | C | ||
+27.53% | 191B | B- | ||
+33.22% | 172B | B- | ||
+9.46% | 164B | C+ | ||
+8.46% | 151B | B- | ||
+8.69% | 136B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAB Stock
- 0H00 Stock
- Ratings Banco de Sabadell